Tuesday 28th June 2022
On 29th June, Scleroderma & Raynaud’s UK will open applications for the Olive Ayoub Intermediate to Late-Stage Post-doctoral Research Fellowship, which will enable one exceptional, non-tenured post-doctoral researcher to transition from postdoc to research leader in the field of scleroderma.
Friday 24th June 2022
A new US study has found that scleroderma patients who test positive for ‘anti-Th/To antibodies’ are at higher risk of developing pulmonary hypertension (PH) in comparison to other patients, which could enable the earlier detection and more effective management of one of scleroderma’s most serious complications.
Wednesday 8th June 2022
Yesterday saw the launch of the Innovative Medicines Fund (IMF) - a scheme which will give NHS patients living in England, including those with rare diseases like Scleroderma, the chance to have ‘early’ access to cutting-edge treatments offering them the best chances of a longer and healthier life.
Thursday 10th June 2021
A coalition of charities, including SRUK has written an open letter to employers, calling for them to put protective measures in place for staff who may have reduced protection from the COVID-19 vaccine.
Friday 26th June 2020
Lenabasum is a synthetic drug that activates a certain receptor involved in the immune system and in the activity of fibroblasts, which drive fibrosis (scarring), and is particularly useful for diffuse cutaneous scleroderma.
Thursday 27th June 2019
Given the role that the lymphatic system plays with the immune system, it has been speculated that lymphatic dysfunction may encourage the development of rheumatic autoimmune diseases, such as scleroderma, lupus and rheumatoid arthritis.
Friday 21st June 2019
Fibrosis is one of the major physical changes that a person living with scleroderma can experience. Its effects are potentially extremely damaging and widespread in the body, it is critical that biomarkers are defined to predict if certain individuals are at risk of developing fibrosis.
Tuesday 11th June 2019
A core pillar of SRUK’s 5-year research strategy is identifying causes behind the development of Raynaud’s and scleroderma. Here we've explored the current research into the potential epigenetic causes of autoimmune conditions like scleroderma.
Thursday 6th June 2019
Despite the similarity of initial symptoms in primary Raynaud’s phenomenon (PRP) and secondary Raynaud’s phenomenon (SRP), the long-term implications of SRP mean that it is critical for there to be more effective assessments that can accurately specify which of the two a person may have.
Tuesday 4th June 2019
Prolonged exposure to hand-transmitted vibration (HTV) can result in hand-arm vibration syndrome (HAVS). When associated with secondary Raynaud’s, this is called vibration white finger, where there is damage to nerves, blood vessels and joints in the hand.
